The Alliance for Patient Access Annual National Policy and Advocacy Summit on Biologics and Biosimilars

Panel Discusses Effort by Administration to Lower Drug Prices

April 13th 2019

During the last panel at the Alliance for Patient Access 4th Annual National Policy and Advocacy Summit on Biologics and Biosimilars, panelists discussed some of the administration’s proposals, such as moving Medicare Part B drugs to Part D, a proposal to end protected drug classes in Medicare, and the International Price Index.

Organization Discusses Impact of Nonmedical Switching on Patients

April 12th 2019

Article

Two leaders of the Alliance for Patient Access discussed results of a survey and focus group about nonmedical switching of patients from one drug to another by payers and pharmacy benefit managers for reasons of cost.

How Patient Advocates Engage Payers in Discussing Value

April 11th 2019

Article

The theme of the Alliance for Patient Access 4th Annual National Policy and Advocacy Summit on Biologics and Biosimilars meeting was all about value, and panelists from the Aimed Alliance and the Partnership to Advance Cardiovascular Health discussed how they used the concept of value in their discussions with payers.

Uptake of Biosimilars in the US: Good News, Bad News

April 10th 2019

Article

At the 4th Annual Policy and Advocacy Summit on Biologics and Biosimilars of the Alliance for Patient Access, speakers discussed the fact that while numerous biosimilars have been approved, most have not reached the market in the United States.

Panelists Grapple With Healthcare Payment Models and Patient Access

April 20th 2018

Article

In a panel during the National Policy and Advocacy Summit on Biologics and Biosimilars, held in Washington, DC, on April 17, rheumatologist Madelaine Feldman, MD; Wayne Winegarden, PhD, of the Pacific Research Institute; and rheumatologist Angus Worthing, MD, chair of the American College of Rheumatology’s Government Affairs Committee, discussed trends in healthcare payment models.

Congressman Buddy Carter is "All In" on Biosimilars

April 19th 2018

Article

At the National Policy and Advocacy Summit on Biologics and Biosimilars, held in Washington, DC, on April 17, Earl “Buddy” Carter, Republican Congressman for Georgia’s first legislative district, highlighted his work to control the price of drugs for patients.

Expert Panel Discusses Challenges With Biosimilar Uptake

April 19th 2018

Article

A panel of health experts discussed the pathway and speed of biosimilar development, as well as the barriers to major uptake of these drugs, during a discussion at the National Policy and Advocacy Summit on Biologics and Biosimilars, held in Washington, DC, on April 17.

FDA's Leah Christl Provides an Agency Perspective on the Biosimilars Landscape

April 18th 2018

Article

Over time, the United States will see a dramatic increase in the number of biosimilar approvals based on the quantity of applications that the FDA is currently receiving, said Leah Christl, PhD, associate director for therapeutic biologics at the Office of New Drugs in the FDA’s Center for Drug Evaluation and Research, at the National Policy and Advocacy Summit on Biologics and Biosimilars held in Washington, DC, on April 17.

Panelists Discuss Roadblocks to Accessing Biologics and Other High-Cost Drugs

April 18th 2018

Article

During a panel session at the National Policy and Advocacy Summit on Biologics and Biosimilars, held in Washington, DC, on April 17, panelists discussed key barriers to accessing biologics and other innovative treatments, as well as how patient advocacy can be leveraged to chip away at those barriers.